Browse by author
Lookup NU author(s): Emeritus Professor David Bates
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Multiple sclerosis is a chronic, demyelinating disorder of the central nervous system. It is characterised by progressive neurological disability, which is likely to occur as a result of permanent axonal damage. Such damage may be reflected by brain atrophy, which can be identified early in the course of the disease. Patients who present with an initial episode of inflammatory demyelination, commonly referred to as a clinically isolated syndrome, are at high risk of developing clinically definite multiple sclerosis, especially if their magnetic resonance imaging studies suggest the presence of multi-focal disease. Treatment with disease-modifying therapies at the initial episode of demyelination may postpone this development. In this review we present an overview of evidence supporting early treatment initiation. We focus on three large placebo-controlled trials of interferon beta therapy: Controlled High-Risk Avonex (R) Multiple Sclerosis Prevention Study, Early Treatment of Multiple Sclerosis and Betaferon (R) in Newly Emerging Multiple Sclerosis for Initial Treatment. Results from these early treatment studies are presented, and the impact of using interferon beta treatment in the early stages of disease is discussed with the aim of considering optimal therapeutic strategies to improve long-term patient outcome.
Author(s): Goodin DS, Bates D
Publication type: Review
Publication status: Published
Journal: Multiple Sclerosis
Year: 2009
Volume: 15
Issue: 10
Pages: 1175-1182
ISSN (print): 1352-4585
ISSN (electronic): 1477-0970
Publisher: SAGE PUBLICATIONS LTD
URL: http://dx.doi.org/10.1177/1352458509107007
DOI: 10.1177/1352458509107007
